Nachrichten zur Kura Oncology Inc. Aktie

Kura Oncology Inc. (KURA)  ist ein Biotechnologieunternehmen, welches sich sich auf die Entwicklung präzisionsmedizinischer Therapien zur Krebsbehandlung konzentriert. Der Fokus…

Kura Oncology stock rises after promising cancer drug combination data…

…

Kura Oncology at ESMO Congress 2025: Promising Cancer Therapies…

…

– Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML…

Kura Oncology (KURA) delivered earnings and revenue surprises of -600.00% and -89.23%, respectively, for the quarter ended June 2025. Do…

SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…

Kura Oncology shares rise this week after the FDA accepts its NDA for ziftomenib, a potential first-in-class treatment for NPM1-mutant…

…

Kura Oncology (KURA) delivered earnings and revenue surprises of 65.08% and 76.49%, respectively, for the quarter ended December 2024. Do…

Kura Oncology Inc. (KURA) ist ein Biotech, welcher sich auf die Entwicklung von Präzisionsmedikamenten zur Behandlung von Krebs spezialisiert hat.…

Kura Oncology tumbles as Kyowa collaboration seen hitting M&A prospects…

…

– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r adverse risk AML patients selected for oral presentation on Saturday,…

SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…

SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…

…

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…

Kura Oncology executive sells over $57k in company stock…

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…

…

SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…

SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical…

Earnings call: Kura Oncology reports promising trial results, financial outlook…

SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical…

…